Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Special Projects for Equitable and Efficient Distribution (SPEED) of COVID-19 Outpatient Therapeutics

The Special Projects for Equitable and Efficient Distribution (SPEED) program supports direct federal allocation of COVID-19 outpatient therapeutics (i.e., monoclonal antibodies [mAbs]) to priority settings that care for populations at high risk for hospitalization. SPEED is separate and complementary to the state-based mAb allocation system. The four priority settings supported by SPEED are: long-term care facilities (LTCF), dialysis centers, federally qualified health centers (FQHCs), and correctional facilities.






Long-term Care
Facilities (LTCF)

Dialysis
Centers

Federally Qualified
Health Centers (FQHCs)​

Correctional
Facilities


Find out how your facility can receive direct federal allocations of mAbs through SPEED. States will receive bi-weekly reports of all participating SPEED facilities in their jurisdiction.




Long-term Care Facilities

SPEED supports LTCFs, including nursing homes and assisted living facilities, through partnerships with stakeholder and/or trade associations who assist with educating members and non-members about mAbs. These organizations also identify entities that are able and willing to administer mAbs. Membership in partner associations is not required for participation in SPEED.

SPEED stakeholder/trade association partners include:

  • National Home Infusion Association (NHIA)
    • NHIA coordinates participation of home infusion providers who (through CMS flexibilities) are now able to provide mAb infusion therapy to eligible individuals residing or working in long-term care facilities, including assisted living facilities
    • Participating home infusion providers can also administer mAbs in other SPEED settings, including dialysis centers, FQHCs, and correctional facilities, depending on local needs and priorities.
    • For more information about this program, including a map of participating home infusion providers, and access to their online application and other tools, visit the NHIA Bamlanivimab Pilot Program webpage.

  • American Society of Consultant Pharmacists (ASCP)
    • ASCP is the trade association for LTC pharmacies (LTCP) and other pharmacies that serve seniors.
    • ASCP coordinates LTCP participation in SPEED.
    • For more information on how to enroll in the LTCP SPEED program, contact ASCP’s Chief Executive Officer Chad Worz at cworz@ascp.com.

  •  AMDA - The Society for Post-Acute and Long-Term Care Medicine
    • AMDA is the association representing medical directors and other clinical providers in nursing homes.
    • AMDA communicates with their members to increase awareness of mAbs and relevant LTC SPEED programs.
    • AMDA helps identify LTCFs that have on-site capacity to receive, store, prepare, and administer mAbs; these sites can then receive mAbs directly through SPEED.
    • Please contact AMDA’s Executive Director, Christopher E. Laxton, at claxton@paltc.org for more information on AMDA.

For more information on the mAbs used and reimbursement, please see the resources section.


Dialysis Centers

All dialysis centers are eligible to participate in SPEED and receive direct allocations of mAbs.

For more information on SPEED and to enroll your company and/or individual dialysis centers in the program, contact covidtx@hhs.gov.

For more information on the mAbs used and reimbursement, please see the resources section.


Federally Qualified Health Centers

FQHCs and look-alikes that have the staffing, supplies, and means to administer mAbs can participate in SPEED and receive direct federal allocations of the products. FQHCs that do not have on-site capabilities to administer mAbs can partner with local hospitals or community infusion centers, who can receive SPEED allocations earmarked for use with FQHC patients only.

Below are resources for FQHCs preparing for mAb infusions:

For more information on SPEED and to enroll your FQHC or partnering facility in the program, see the SPEED Enrollment Guide

For more information on the mAbs used and reimbursement, please see the resources section.


State and Local Correctional Facilities

State and local correctional facilities, including prisons and jails, that have the staffing, supplies, and means to administer mAb infusions on site can participate in SPEED. The program supports multiple distribution models, depending on the needs and infrastructure of respective state/local department of corrections, or equivalent. These models include:

  • Direct shipments to facilities with on-site capacity to receive, store, prepare, and administer mAbs.
  • Shipments to contract correctional healthcare providers and/or pharmacies.
  • Shipments to local pharmacies serving correctional facilities.

HHS/ASPR is partnering with the American Correctional Association (ACA) to increase awareness about SPEED and encourage member organizations to participate.

For more information on SPEED and to enroll your facility or partnering pharmacy in the program, contact covidtx@hhs.gov.

For more information on the mAbs used and reimbursement, please see the resources section.

Resources

 

  • This page last reviewed: February 24, 2021